

# Ahmed M Soliman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11666315/publications.pdf>

Version: 2024-02-01

78  
papers

2,291  
citations

218677

26  
h-index

243625

44  
g-index

78  
all docs

78  
docs citations

78  
times ranked

1623  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Benefit/Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184.	3.0	22
2	Impact of endometriosis on women's life decisions and goal attainment: a cross-sectional survey of members of an online patient community. <i>BMJ Open</i> , 2022, 12, e052765.	1.9	12
3	Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 297-306.e2.	0.6	11
4	Impact of Endometriosis on Fatigue and Productivity Impairment in a Cross-Sectional Survey of Canadian Women. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 10-18.	0.7	18
5	A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 40-47.	2.5	2
6	Impact of pain and nonpain co-morbidities on opioid use in women with endometriosis. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 17-27.	1.4	1
7	Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. <i>Fertility and Sterility</i> , 2021, 115, 423-430.	1.0	5
8	Real-world characteristics of women with endometriosis-related pain entering a multidisciplinary endometriosis program. <i>BMC Women's Health</i> , 2021, 21, 19.	2.0	16
9	Impact of Endometriosis on Life-Course Potential: A Narrative Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9-25.	1.8	75
10	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	3.0	40
11	Development of a visual, patient-reported tool for assessing the multi-dimensional burden of endometriosis. <i>Current Medical Research and Opinion</i> , 2021, 37, 1443-1449.	1.9	6
12	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	1.2	36
13	Treatment patterns of women with endometriosis in Canada. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2021, 13, 25-31.	0.5	1
14	Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 531-539.	1.4	4
15	National Patterns of Emergency Department Use for Women with Endometriosis, 2006-2015. <i>Journal of Women's Health</i> , 2020, 29, 420-426.	3.3	2
16	A survey of care pathway and health-related quality of life impact for children with central precocious puberty. <i>Current Medical Research and Opinion</i> , 2020, 36, 411-418.	1.9	8
17	Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 592.e1-592.e10.	1.3	26
18	Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials. <i>Journal of Women's Health</i> , 2020, 29, 253-261.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Clinically Meaningful Reduction in Dyspareunia Is Associated with Significant Improvements in Health-Related Quality of Life Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix. <i>Journal of Sexual Medicine</i> , 2020, 17, 2427-2433.	0.6	9
20	&lt;p&gt;Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database&lt;/p&gt;. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 473-479.	1.9	7
21	Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase <sc>III</sc> Trials to an Older Realâ€World Population. <i>JBMR Plus</i> , 2020, 4, e10401.	2.7	4
22	Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix. <i>Obstetrics and Gynecology</i> , 2020, 136, 501-509.	2.4	14
23	Elagolix in the treatment of endometriosis: impact beyond pain symptoms. <i>Therapeutic Advances in Reproductive Health</i> , 2020, 14, 263349412096451.	2.1	5
24	Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 21, 1-9.	1.4	3
25	Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA. <i>Advances in Therapy</i> , 2020, 37, 2777-2791.	2.9	3
26	Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1754-1759.	3.0	2
27	A Longitudinal Assessment of the Impact of Endometriosis on Patientsâ€™ Salary Growth and Risk of Leaving the Workforce. <i>Advances in Therapy</i> , 2020, 37, 2144-2158.	2.9	8
28	Cross-Sectional Survey of the Impact of Endometriosis Symptoms on Health-Related Quality of Life in Canadian Women. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 1330-1338.	0.7	11
29	Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. <i>New England Journal of Medicine</i> , 2020, 382, 328-340.	27.0	138
30	Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs. <i>Advances in Therapy</i> , 2020, 37, 1087-1099.	2.9	60
31	Prevalence, Symptomatic Burden, and Diagnosis of Endometriosis in Canada: Cross-Sectional Survey of 30â€000 Women. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 829-838.	0.7	48
32	Patientsâ€™ perspectives of endometriosis-related fatigue: qualitative interviews. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 33.	1.9	9
33	Psychometric assessment of the PROMIS Fatigue Short Form 6a in women with moderate-to-severe endometriosis-associated pain. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 86.	1.9	5
34	The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States. <i>Women's Health</i> , 2020, 16, 174550652096589.	1.5	5
35	Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2019, 11, 117-125.	0.5	1
36	A longitudinal assessment of the impact of endometriosis on patientsâ€™ salaries. <i>Fertility and Sterility</i> , 2019, 112, e321.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials. <i>Patient</i> , 2019, 12, 651-660.	2.7	9
38	National trends in inpatient endometriosis admissions: Patients, procedures and outcomes, 2006â€”2015. <i>PLoS ONE</i> , 2019, 14, e0222889.	2.5	10
39	Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2019, 11, 171-180.	0.5	3
40	Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. <i>Fertility and Sterility</i> , 2019, 112, 545-551.	1.0	11
41	Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 836-846.	0.9	3
42	Patient Preferences for Endometriosis Pain Treatments in the United States. <i>Value in Health</i> , 2019, 22, 728-738.	0.3	12
43	Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 566-572.	0.9	20
44	Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. <i>Fertility and Sterility</i> , 2019, 112, 298-304.e3.	1.0	24
45	Costâ€”effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 337-355.	1.4	12
46	Patterns of Prescription Opioid Use in Women With Endometriosis. <i>Obstetrics and Gynecology</i> , 2019, 133, 1120-1130.	2.4	37
47	Review and evaluation of patient-centered psychosocial assessments for children with central precocious puberty or early puberty. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2018, 31, 485-495.	0.9	28
48	Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States. <i>Advances in Therapy</i> , 2018, 35, 408-423.	2.9	93
49	Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. <i>Obstetrics and Gynecology</i> , 2018, 132, 1252-1264.	2.4	51
50	Development of the Painful Periods Screening Tool for endometriosis. <i>Postgraduate Medicine</i> , 2018, 130, 694-702.	2.0	5
51	Risk of Developing Comorbidities Among Women with Endometriosis: A Retrospective Matched Cohort Study. <i>Journal of Women's Health</i> , 2018, 27, 1114-1123.	3.3	60
52	Baseline Burden of Endometriosis-Associated Pain among Women in Two Phase 3 Elagolix Studies [10Q]. <i>Obstetrics and Gynecology</i> , 2018, 131, 186S-187S.	2.4	2
53	Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain. <i>Reproductive Sciences</i> , 2018, 25, 1567-1576.	2.5	17
54	Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids. <i>Journal of Women's Health</i> , 2018, 27, 1204-1214.	3.3	33

#	ARTICLE	IF	CITATIONS
55	Long-Term Outcomes of Elagolix in Women With Endometriosis. <i>Obstetrics and Gynecology</i> , 2018, 132, 147-160.	2.4	91
56	The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2017, 38, 238-248.	2.1	110
57	Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States. <i>Fertility and Sterility</i> , 2017, 107, 1181-1190.e2.	1.0	34
58	Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. <i>Journal of Women's Health</i> , 2017, 26, 644-654.	3.3	18
59	Factors Associated with Time to Endometriosis Diagnosis in the United States. <i>Journal of Women's Health</i> , 2017, 26, 788-797.	3.3	92
60	Patient-completed or symptom-based screening tools for endometriosis: a scoping review. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 153-165.	1.7	37
61	Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. <i>Fertility and Sterility</i> , 2017, 108, 152-160.e4.	1.0	64
62	Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis. <i>Advances in Therapy</i> , 2017, 34, 2436-2451.	2.9	23
63	Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. <i>Current Medical Research and Opinion</i> , 2017, 33, 1971-1978.	1.9	46
64	Examining the Relationship Between Symptomatic Burden and Self-reported Productivity Losses Among Patients With Uterine Fibroids in the United States. <i>Journal of Occupational and Environmental Medicine</i> , 2017, 59, 974-981.	1.7	9
65	Changes in Healthcare Spending After Diagnosis of Comorbidities Among Endometriosis Patients: A Difference-in-Differences Analysis. <i>Advances in Therapy</i> , 2017, 34, 2491-2502.	2.9	6
66	Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. <i>Gynecologic and Obstetric Investigation</i> , 2017, 82, 453-461.	1.6	190
67	Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. <i>Current Medical Research and Opinion</i> , 2017, 33, 193-200.	1.9	18
68	Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. <i>International Journal of Women's Health</i> , 2017, Volume 9, 403-411.	2.6	35
69	The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 745-754.	0.9	91
70	Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 573-587.	0.9	3
71	Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy. <i>Current Medical Research and Opinion</i> , 2016, 32, 1073-1082.	1.9	5
72	The direct and indirect costs associated with endometriosis: a systematic literature review. <i>Human Reproduction</i> , 2016, 31, 712-722.	0.9	143

#	ARTICLE	IF	CITATIONS
73	Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. <i>Fertility and Sterility</i> , 2015, 103, 163-171.	1.0	70
74	The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 141-160.	1.3	73
75	Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. <i>Current Medical Research and Opinion</i> , 2015, 31, 1719-1731.	1.9	21
76	Pharmacist-managed protocol to implement simvastatin labeling changes in a family medicine clinic. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1248-1251.	1.0	0
77	Patient Characteristics Predicting the Frequency of Medication Therapy Management Visits for Patients With Diabetes. <i>Clinical Therapeutics</i> , 2013, 35, 534-540.	2.5	3
78	Optimal Diabetes Care Outcomes Following Face-to-Face Medication Therapy Management Services. <i>Population Health Management</i> , 2013, 16, 28-34.	1.7	49